Sequenom to Lead in the NIPD Market

Thursday 6 September 2012, Amsterdam

According to a research report entitled, "US Non-Invasive Prenatal Diagnostics - Market Insight", Sequenom is expected to remain the undefeated market leader in the US NIPD market. Sequenom markets its MaterniT21 test in the NIPD market that analyzes circulating cell-free DNA extracted from a maternal blood sample utilizing massively parallel sequencing. The product was amongst the first NIPD tests available and has presented Sequenom with an undefeated market presence. With growing demands for such non-invasive tests, Sequenom is expected to continue to be the market leader in the NIPD segment in the future as well.

The US Non-invasive prenatal diagnostic market is a relatively new sector in the diagnostics industry. Currently, the NIPD market is represented by only a few companies such as Sequenom, Verinata and Ariosa diagnostics. One of the promising new market entrants is Natera. The sector has a highly untapped potential and is expected that it will evolve greatly in the future. Research and innovation in the sector is very robust and there are several clinical trials being undergone at present. Regulatory intervention is weak as NIPD tests are classified as Lab Developed Tests (LDTs) that do not require FDA regulation. According to a latest report by RNCOS, "US Non-Invasive Prenatal Diagnostics - Market Insight", the US NIPD market is expected to show a double-digit growth from 2012-2016.

The report spread in over 55 pages provides an in-depth research and rational analysis of the current status and expected position of the US NIPD Market. It facilitates the future forecasts on the overall US NIPD Market size by 2016 and takes into account pessimistic and optimistic scenarios that could prevail in the market. Moreover, it also projects the potential market to be tapped by currently active market players. Opportunity assessment for companies in the US NIPD Market in terms of leading technologies is also analyzed in the report. In addition, the report elaborates on the ongoing clinical trials and the various restraints faced by the sector. To provide a holistic view, it also provides a competitive assessment of the major players describing their key business and comparing their strengths and weaknesses.